



Agilis Biotherapeutics Presents at Canadian Angelman Syndrome Society International Meeting

Cambridge, MA, July 22, 2016 -- Agilis Biotherapeutics, LLC (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), announced today that Agilis presented a company and research update during the Canadian Angelman Syndrome Society (CASS) International Meeting held July 14-16 2016. Christopher Silber, MD, Chief Medical Officer of Agilis, gave a presentation highlighting Agilis' collaboration on Angelman Syndrome gene therapy with Edwin Weeber, Ph.D., Professor, Molecular Pharmacology and Physiology, Chief Scientific Officer, USF Health Byrd Alzheimer's Institute and Director, Neurobiology of Learning and Memory Laboratory at the University of South Florida. Dr. Weeber has published recent scientific findings on potential treatment approaches for Angelman Syndrome with gene therapy using the UBE3A gene. Dr. Silber reviewed Agilis' recent progress and the drug development process for gene therapy before an audience of families, clinicians and scientists.

"Agilis is honored to participate in this meeting," said Dr. Silber. "The Canadian Angelman Syndrome Society is an inspiring organization committed to helping the Angelman community in a myriad of ways. We are thrilled to be able to partner with them and to continue to focus on progressing our gene therapy program for Angelman syndrome."

CASS is an organization of families and professionals dedicated to finding a cure for Angelman syndrome and related disorders through the funding of an aggressive research agenda, education, and advocacy.

About Agilis Biotherapeutics, LLC

Agilis is advancing innovative gene therapies designed to provide long-term efficacy for patients with debilitating, often fatal, rare genetic diseases that affect the central nervous system. Our therapies are engineered to impart sustainable clinical benefits, and potentially a functional cure, by inducing persistent expression of a therapeutic gene. The Company's technology is aimed at the precise targeting and restoration of a lost gene function, while avoiding unintended off-target effects. Our integrated strategy increases the efficiency of developing DNA therapeutics into safe, targeted gene therapies that achieve long-term efficacy and enable patients to remain asymptomatic without continuous invasive treatment. Agilis' rare disease programs are focused on gene therapy for AADC deficiency, Friedreich's ataxia, Angelman syndrome, and Fragile X syndrome, rare genetic diseases that include severe neurological deficits and result in physically debilitating conditions.

We invite you to visit our website at www.agilisbio.com

###

For more information contact:

Agilis Biotherapeutics

Dr. Jodi Cook

Vice President, Operations & Strategic Alliances

Email: jcook@agilisbio.com

Phone: 510-673-7809